ArticleClinical oral investigations2025
Effect of nonsurgical periodontal treatment on NLRP3, Nrf2, Caspase-1, interleukin-1B, interleukin-18 in gingival crevicular fluid of severe periodontitis.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Silent Inflammation: A Critical Narrative Review of the Relationship Between Periodontal Disease and Psychosis-The Role of Oxidative Stress and Iatrogenic Comorbidities.Antioxidants (Basel, Switzerland) · 2026Review
- Non-antibiotic lipid complex-in-thermogel strikes twice: multimodal photosensitive antibacterial meets immunomodulation-boosted healing for periodontitis treatment.Materials today. Bio · 2026Article
- Periodontitis and MASLD: a narrative review of the direct oral-hepatic pathway.Frontiers in cellular and infection microbiology · 2026Review
- Targeting pyroptosis in periodontitis: mechanisms and therapeutic strategies.Frontiers in immunology · 2026Review
- The inflammation-pyroptosis axis links local and systemic biomarker profiles to active alveolar bone microstructural deterioration.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe signaling pathways activated in periodontitis is important to treat or to prevent the disease. Recent data have established the role of inflammasomes in periodontitis. The purpose of this study was to determine the concentrations of NLRP3, IL-1β, IL-18, Caspase-1, and Nrf2 in gingival-crevicular-fluid (GCF) from patients with Stage3 periodontitis following nonsurgical-periodontal-treatment (NSPT), to compare them with clinical periodontal parameters, and to evaluate these parameters as potential biomarkers of response to NSPT.
methodsA total of 129 individuals (Healthy, n:64; periodontitis, n:65) involved in the study. GCF was collected from the distal and mesial regions of 5 single-rooted anterior teeth and clinical periodontal parameters [plaque index(PI), bleeding-on-probing(BOP), probing-pocket-depth(PPD) and clinical-attachment-loss(CAL)] were obtained before and 6 month after NSPT. Levels of biochemical parameters (NLRP3, IL-18, IL-1β, Caspase-1 and Nrf2) were evaluated in GCF samples by ELISA.
resultsAll biochemical and clinical periodontal parameters decreased significantly in the periodontitis group after NSPT (P < 0.001). Except for PI, IL-1β and IL-18, all parameters were significantly higher in the Post-Treatment groups compared to the Healthy group (P < 0.001). IL-1β and IL-18 reached healthy levels with 6-month follow-up of NSPT. All biochemical parameters were significantly correlated with full-mouth clinical periodontal parameters in the Pre-Treatment and Post-Treatment groups (P < 0.01).
conclusionThe tested biochemical parameters play important roles in the pathogenesis of periodontitis. IL-1β and IL-18 support their potential as clinically important biomarkers for treatment monitoring. Elevated levels of NLRP3, Caspase-1, and Nrf2 may indicate ongoing inflammatory activity rather than complete resolution after treatment. Clinical applicability must be confirmed by larger, longitudinal studies using advanced molecular techniques. CLINICAL RELEVANCE: Monitoring the decrease of IL-1β and IL-18 with NSPT in GCF samples may indicate that these markers are promising treatment follow-up biomarkers.
Indexed as
Identifiers
40996467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.